All Oncology News

Newer drugs for patients with relapsed and refractory Hodgkin lymphoma

The FDA has updated the label for obinutuzumab plus chlorambucil to include data from stage 2 of the phase III CLL11 study, which detailed an unprecedented improvement in progression-free survival compared with rituximab plus chlorambucil as a frontline treatment for patients with chronic lymphocytic leukemia.

Rituximab dose should be based on age and sex.

Researchers will dissect topline results from the MARIANNE trial in the coming weeks in an effort to understand why T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to triumph as a first-line treatment in the metastatic setting for patients with advanced HER2-positive breast cancer despite the promise of earlier findings

The FDA has approved the PD-1 inhibitor nivolumab for patients with unresectable or metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor.

Only 10% of current medical students aspire to open up shop as a solo practitioner-a 50% drop since 2008. Last year, 17% of students surveyed said that solo practice was a consideration. On the other hand, those students who anticipate seeking employment with a large group practice or hospital has risen to 73%, as compared with 70% last year.

The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer.

Two HER2-targeting regimens anchored by T-DM1 (ado-trastuzumab emtansine; Kadcyla) failed to outperform the standard strategy in women with previously untreated advanced HER2-positive breast cancer in the MARIANNE trial, dealing a blow to efforts to move the drug into frontline settings.

The FDA has approved lanreotide for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.

The FDA has approved the VEGFR-2 inhibitor ramucirumab (Cyramza) in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumor has progressed during or following treatment with platinum-based chemotherapy.

Actor and singer Charles Esten, whose daughter was diagnosed with leukemia when she was two and a half, shares the challenging and painful experiences of battling the disease.

Physicians' Education Resource®, LLC (PER®), to Sponsor Innovative CME Conference for Breast Cancer Specialists

The FDA has approved the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

The FDA has approved the bispecific T cell engager antibody blinatumomab as a treatment for adult patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

Despite the proven benefits of stereotactic body radiotherapy (SBRT) for patients with inoperable stage I non–small cell lung cancer (NSCLC), whether such patients are offered it depends on their race, insurance status, and the type of facility where they are being treated.

Award reception and gala will recognize the work and achievements of individuals dedicated to improving the lives of people living with rare blood disorders

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

The treatment of patients with multiple myeloma is poised to undergo a dramatic transformation, as novel monoclonal antibodies and combination strategies race toward approval.

Pfizer and Merck KGaA have agreed to collaborate on the development of the PD-L1 inhibitor MSB0010718C as a potential treatment for multiple types of cancer.

Entrepreneur James Feldman, chief innovation officer of the Chicago-based company Shift Happens!, calls himself "a doctor for business."

The FDA has extended the review period for panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone for patients with previously treated multiple myeloma by 3 months, placing a new decision date in early 2015.

Urologists hear quite a bit about risk from the legislative and regulatory angles.

The chimeric antigen receptor (CAR) T cell therapy JCAR015 has received a breakthrough therapy designation from the FDA as a treatment for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

The FDA has granted an orphan drug designation to the novel AXL inhibitor BGB324 (R428) for the treatment of patients with acute myeloid leukemia (AML).

The IDH1 inhibitor AG-120 has shown a favorable safety and efficacy profile in patients with IDH1 mutation positive advanced hematologic malignancies, including acute myeloid leukemia (AML).

Recent advances with immune checkpoint inhibitors could improve outcomes for patients with squamous cell non-small cell lung cancer, a traditionally hard to treat histology.

Adding 1-year of adjuvant trastuzumab to chemotherapy continues to demonstrate an improvement in overall survival (OS) and disease-free survival (DFS) for patients with early-stage HER2-positive breast cancer

Treatment with the antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) has demonstrated promising clinical efficacy with lower toxicity across a variety of settings for patients with HER2-positive metastatic breast cancer when compared with standard therapies.

Juno Therapeutics, Inc, has filed a registration statement for an initial public offering of its common stock, as its early stage therapies continue to advance in clinical trials.

The FDA has granted MM-398 (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer